Business
Todos Medical Announces Voting Results from 2019 Annual Shareholder Meeting
Todos Medical Announces Voting Results from 2019 Annual Shareholder Meeting.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\nREHOVOT, Israel and NEW YORK, May 03, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that Todos Medical’s Annual Shareholder Meeting was held on Monday, April 29, 2019.\n Shareholders adopted all of the proposals submitted for their approval. The proposals included: Approval of completion of acquisition of Breakthrough Diagnostics, Inc. from Amarantus Bioscience Holdings, Inc.Approval of loan conversion transaction with a current debt holder to convert $350,000 in debt to an equity position.Re-election of the Board of Directors.Adoption of a Compensation Policy for the Company.Re-appointment of Fahn Kanne & Co. Grant Thornton, Israel as the Company’s independent auditor. “This has been an exciting year for Todos Medical as we have moved forward on many key initiatives. The highlights of which are the advancement of our technology to the point of beginning the commercialization phase of our breast cancer screening product as well as the acquisition of Breakthrough Diagnostics, Inc., which expands our technology to the field of neurodegenerative disorders,” said Dr. Herman Weiss, President & CEO of Todos. “I would like to thank our entire team for their tremendous efforts in helping Todos Medical further its core objective of developing blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease.” About Todos Medical Ltd.Todos Medical Ltd. (OTCQB: TOMDF), an Israeli company headquartered in Rehovot, is an in-vitro-diagnostic (“IVD”) company engaged in the development of a series of blood tests for the early detection of a variety of cancers and neurodegenerative disorders, such as Alzheimer's disease. The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells (“PBMC”) and plasma. This proprietary and patented method incorporates biochemistry...